New drug hopes to rally immune system against tough cancers

NCT ID NCT06882746

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times

Summary

This early-stage trial tests a new medicine, BI 765049, in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest safe dose and best way to give the drug. BI 765049 is designed to help the immune system attack cancer cells. Participants receive the drug at least every 3 weeks and may continue as long as it helps and is tolerable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Valkyrie Clinical Trials

    RECRUITING

    Los Angeles, California, 90067, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.